Table 1 Patient baseline characteristics
From: Design and validation of a disease network of inflammatory processes in the NSG-UC mouse model
Donor | Treatment | SCCAI | Age | Gender | Time since diagnosis |
|---|---|---|---|---|---|
1 | Infliximab, glucocorticoid, mesalazine | 5 | 36 | w | 12 |
2 | No | 10 | 52 | m | 21 |
3 | No | 5 | 52 | m | 21 |
4 | Colectomy, loperamid, mesalazine, | Â | 46 | w | 20 |
5 | Infliximab, glucocorticoid, mesalazine | 11 | 36 | w | 12 |
6 | Adalimumab, mesalazine | 5 | 35 | m | 16 |
7 | Infliximab | 2 | 68 | w | 38 |
8 | Adalimumab | 3 | 53 | w | 13 |